JP2013537174A5 - - Google Patents

Download PDF

Info

Publication number
JP2013537174A5
JP2013537174A5 JP2013527575A JP2013527575A JP2013537174A5 JP 2013537174 A5 JP2013537174 A5 JP 2013537174A5 JP 2013527575 A JP2013527575 A JP 2013527575A JP 2013527575 A JP2013527575 A JP 2013527575A JP 2013537174 A5 JP2013537174 A5 JP 2013537174A5
Authority
JP
Japan
Prior art keywords
amino
imidazo
cyclopropyl
methylbenzamide
pyridazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013527575A
Other languages
English (en)
Japanese (ja)
Other versions
JP5824050B2 (ja
JP2013537174A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/065368 external-priority patent/WO2012032031A1/en
Publication of JP2013537174A publication Critical patent/JP2013537174A/ja
Publication of JP2013537174A5 publication Critical patent/JP2013537174A5/ja
Application granted granted Critical
Publication of JP5824050B2 publication Critical patent/JP5824050B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013527575A 2010-09-10 2011-09-06 置換イミダゾピリダジン類 Expired - Fee Related JP5824050B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP10176134.4 2010-09-10
EP10176134 2010-09-10
EP11075022.1 2011-02-04
EP11075022 2011-02-04
EP11170775.8 2011-06-21
EP11170775 2011-06-21
EP11170771 2011-06-21
EP11170771.7 2011-06-21
PCT/EP2011/065368 WO2012032031A1 (en) 2010-09-10 2011-09-06 Substituted imidazopyridazines

Publications (3)

Publication Number Publication Date
JP2013537174A JP2013537174A (ja) 2013-09-30
JP2013537174A5 true JP2013537174A5 (https=) 2014-10-09
JP5824050B2 JP5824050B2 (ja) 2015-11-25

Family

ID=44545741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013527575A Expired - Fee Related JP5824050B2 (ja) 2010-09-10 2011-09-06 置換イミダゾピリダジン類

Country Status (38)

Country Link
US (1) US9255100B2 (https=)
EP (1) EP2614063B1 (https=)
JP (1) JP5824050B2 (https=)
KR (1) KR20140032337A (https=)
CN (1) CN103370318B (https=)
AP (1) AP3607A (https=)
AR (1) AR082946A1 (https=)
AU (1) AU2011298844B2 (https=)
BR (1) BR112013005679A2 (https=)
CA (1) CA2810755A1 (https=)
CO (1) CO6720961A2 (https=)
CR (1) CR20130102A (https=)
CU (1) CU24187B1 (https=)
CY (1) CY1117352T1 (https=)
DK (1) DK2614063T3 (https=)
DO (1) DOP2013000054A (https=)
EA (1) EA023420B1 (https=)
EC (1) ECSP13012752A (https=)
ES (1) ES2568220T3 (https=)
HR (1) HRP20160360T1 (https=)
HU (1) HUE028771T2 (https=)
IL (1) IL225058A (https=)
MA (1) MA34516B1 (https=)
ME (1) ME02389B (https=)
MX (1) MX2013002713A (https=)
MY (1) MY185139A (https=)
NZ (1) NZ607904A (https=)
PE (1) PE20131164A1 (https=)
PH (1) PH12013500454A1 (https=)
PL (1) PL2614063T3 (https=)
RS (1) RS54661B1 (https=)
SA (1) SA111320735B1 (https=)
SG (1) SG188417A1 (https=)
SI (1) SI2614063T1 (https=)
TW (1) TWI541243B (https=)
UY (1) UY33598A (https=)
WO (1) WO2012032031A1 (https=)
ZA (1) ZA201301756B (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
EP2734205B1 (en) 2011-07-21 2018-03-21 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
CN104284896B (zh) * 2012-03-14 2016-06-01 拜耳知识产权有限责任公司 取代的咪唑并哒嗪
ES2704744T3 (es) 2012-06-13 2019-03-19 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9573954B2 (en) 2012-11-16 2017-02-21 University Health Network Pyrazolopyrimidine compounds
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
TW201437211A (zh) * 2013-03-01 2014-10-01 Bayer Pharma AG 經取代咪唑并嗒□
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
RS56034B1 (sr) 2013-06-11 2017-09-29 Bayer Pharma AG Derivati prolekova supstituisanih triazolopiridina
CN105392484A (zh) * 2013-06-13 2016-03-09 拜耳制药股份公司 咪唑并哒嗪衍生物与有丝分裂试剂的联用药用于治疗癌症
CN103360399B (zh) * 2013-08-02 2016-03-02 北京大学 6-芳基取代-咪唑-[1,2-b]哒嗪类衍生物,其制备方法及用途
GB201321734D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
SG11201606869TA (en) * 2014-02-21 2016-09-29 Frost Biolog Inc Antimitotic amides for the treatment of cancer and proliferative disorders
WO2015157955A1 (en) * 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
TW201613927A (en) * 2014-09-01 2016-04-16 Bayer Pharma AG Method for preparation of substituted imidazopyridazines
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MX373169B (es) 2015-02-20 2020-04-24 Incyte Holdings Corp Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
FI3283642T3 (fi) 2015-04-17 2024-01-11 Crossfire Oncology Holding B V Prognostisia biomarkkereita ttk-inhibiittorikemoterapiaan
WO2016187028A1 (en) * 2015-05-15 2016-11-24 Celgene Avilomics Research, Inc. Heteroaryl compounds, synthesis thereof, and intermediates thereto
BR112018010271A2 (pt) * 2015-12-04 2018-11-27 Exxonmobil Research And Engineering Company material cristalino sintético emm-28, sua preparação e uso
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
AU2017299850B2 (en) * 2016-07-18 2021-05-27 University Health Network Solid forms of TTK inhibitor
WO2018189185A1 (en) * 2017-04-11 2018-10-18 Straumann Holding Ag Dental implant
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CR20200590A (es) 2018-05-04 2021-04-26 Incyte Corp Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
ES2992256T3 (es) 2018-05-08 2024-12-11 Nippon Shinyaku Co Ltd Compuestos de azabencimidazol y producto farmacéutico
US12419865B2 (en) 2018-12-06 2025-09-23 Arisan Therapeutics Inc. Compounds for the treatment of arenavirus infection
NZ778055A (en) 2019-02-12 2025-11-28 Sumitomo Pharma America Inc Formulations comprising heterocyclic protein kinase inhibitors
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
CN111978325B (zh) * 2019-05-22 2023-11-17 中国药科大学 咪唑并哒嗪类mnk1/mnk2激酶抑制剂及其制备方法和应用
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為fgfr抑制劑之雙環雜環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
BR112022008571A2 (pt) 2019-11-13 2022-08-09 Nippon Shinyaku Co Ltd Composto de azabenzimidazol e medicamento
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含fgfr抑制劑及nectin-4靶向劑之組合療法
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
KR20240107189A (ko) * 2021-12-15 2024-07-08 신라젠(주) 신생물성 질환 치료에 사용하기 위한 약제학적 병용물
EP4651950A1 (en) * 2023-01-19 2025-11-26 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127566A0 (en) 1996-08-28 1999-10-28 Pfizer Substituted 6,5-hetero- bicyclic derivatives
WO2001083481A1 (en) 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
US7132426B2 (en) 2003-07-14 2006-11-07 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20090023737A1 (en) 2004-02-12 2009-01-22 Neurogen Corporation Imidazo-Pyridazines, Triazolo-Pyridazines and Related Benzodiazepine Receptor Ligands
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
TW200804386A (en) * 2005-11-10 2008-01-16 Schering Corp Imidazopyrazines as protein kinase inhibitors
TW200840584A (en) * 2006-12-26 2008-10-16 Gilead Sciences Inc Pyrido(3,2-d)pyrimidines useful for treating viral infections
US8546394B2 (en) * 2007-04-17 2013-10-01 Bristol-Myers Squibb Company Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors
EP2217601A1 (en) 2007-11-08 2010-08-18 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyridazines for use as protein kinase inhibitors
WO2009100375A1 (en) 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
CN102413831B (zh) 2009-04-29 2014-06-04 拜耳知识产权有限责任公司 取代的咪唑并喹喔啉
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
CA2772790C (en) 2009-09-04 2017-06-27 Benjamin Bader Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343295A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
US9468642B2 (en) 2010-03-18 2016-10-18 Bayer Intellectual Property Gmbh Imidazopyrazines
ES2555261T3 (es) 2010-06-01 2015-12-30 Bayer Intellectual Property Gmbh Imidazopirazinas sustituidas
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
US9284317B2 (en) 2010-12-17 2016-03-15 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors
JP5822944B2 (ja) 2010-12-17 2015-11-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 過剰増殖性障害の治療におけるmps−1およびtkk阻害剤として使用するための2置換イミダゾピラジン
ES2530802T3 (es) 2010-12-17 2015-03-06 Bayer Ip Gmbh Imidazopirazinas 6-tiosustituidas para uso como inhibidores de MPS-1 y TKK en el tratamiento de trastornos hiperproliferativos
JP2013545779A (ja) 2010-12-17 2013-12-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過剰増殖性障害の治療におけるmps−1およびtkk阻害剤として使用するための6置換イミダゾピラジン
CN103415518A (zh) 2010-12-17 2013-11-27 拜耳知识产权有限责任公司 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的咪唑并吡嗪
CA2821834A1 (en) 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders

Similar Documents

Publication Publication Date Title
JP2013537174A5 (https=)
JP6473457B2 (ja) Shp2の活性を阻害するための1−(トリアジン−3−イル/ピリダジン−3−イル)−ピペリジン/ピペラジン誘導体およびその組成物
US10975080B2 (en) Compounds and compositions for inhibiting the activity of SHP2
CN109415360B (zh) 用于抑制shp2活性的化合物和组合物
US9926314B2 (en) Compounds and compositions for the treatment of parasitic diseases
US9555031B2 (en) Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity
HRP20160360T1 (hr) Supstituirani imidazopiridazini
US20180289685A1 (en) Combinations of inhibitors of irak4 with inhibitors of btk
TWI682930B (zh) 治療性雜環化合物
ES2946060T3 (es) Compuestos y composiciones de urea como inhibidores de SMARCA2/BRM-ATPASA
JP6529492B2 (ja) 癌の処置のためのidh2突然変異体阻害剤としての2,4−または4,6−ジアミノピリミジン化合物
JP2016505529A5 (https=)
US20150291598A1 (en) Compounds and compositions for the treatment of parasitic diseases
JP2018517746A (ja) Shp2の活性を阻害するための化合物および組成物
JP2017502993A (ja) Shp2の活性を阻害するためのn−アザスピロシクロアルカン置換n−ヘテロアリール化合物および組成物
JP2016522232A5 (https=)
TW200908969A (en) Organic compounds
EA019064B1 (ru) Способы лечения рака с применением хинаксолинового ингибитора pi3k-альфа
JP2019507122A (ja) クリプトスポリジウム症の治療のための化合物および組成物
JPWO2021021986A5 (https=)
JPWO2020052631A5 (https=)
RU2021107655A (ru) Соединения триазоло-пиримидина и их применение